Results 211 to 220 of about 10,094,999 (302)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Evidence asymmetry in Australian public spending: why health alone cannot bear a higher burden of proof. [PDF]

Front Public Health
Lee L, Byrnes J, Stewart M, Snoke M, Kim H.   +4 more
europepmc   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

Area-based measures of socioeconomic status in studies assessing health outcomes among people living with HIV in Canada and the USA: a scoping review. [PDF]

BMJ Open
Naidu N, Golzar N, Emerson SD, Budu MO, Hansen S, Branion-Calles M, McLinden T, Hogg RS, Kooij KW.   +8 more
europepmc   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Assessing the impact of co-created community initiatives on health and equity: a protocol for population-based surveys within the CAIR project in Elche, Spain. [PDF]

Front Public Health
Moreno-Llamas A, Navarro-Aranda N, Sanchís-Ramón MJ, Chilet-Rosell E, Lumbreras B, Blanes-Mira C, López Pintor E, Hernández-Aguado I, Parker LA.   +8 more
europepmc   +1 more source

University students' awareness of the social dimension of sustainable transportation: The case of Amasya/Turkey. [PDF]

PLoS One
Şendoğdu S, Nergiz C.
europepmc   +1 more source

Work meaning in medicine: a comparative investigation across training stages. [PDF]

Front Med (Lausanne)
Kovaks N, Lipshits-Braziler Y, Amram-Vaknin S, Gutentag T.   +3 more
europepmc   +1 more source

COVID-19 alert level systems-Lessons learnt for future public health emergencies: A qualitative study. [PDF]

PLoS One
Rohan H, Bochner AF, Brown L, Ortiz EM, McClelland A.   +4 more
europepmc   +1 more source